###begin article-title 0
###xml 41 46 41 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
The -786T>C promoter polymorphism of the NOS3 gene is associated with prostate cancer progression
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 74 79 74 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 167 172 167 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
There is no biological or epidemiological data on the association between NOS3 promoter polymorphisms and prostate cancer. The polymorphisms in the promoter region of NOS3 gene may be responsible for variations in the plasma NO, which may promote cancer progression by providing a selective growth advantage to tumor cells by angiogenic stimulus and by direct DNA damage.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 32 37 32 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 130 135 130 135 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 196 199 196 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA</italic>
###xml 302 310 <span type="species:ncbi:9606">patients</span>
This study aimed evaluating the NOS3 promoter polymorphisms by PCR-SSCP and sequencing, associating genotypes and haplotypes with NOS3 expression levels through semi-quantitative RT-PCR, and with PCA3 mRNA detection, a specific tumor biomarker, in the peripheral blood of pre-surgical samples from 177 patients; 83 PCa and 94 BPH.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 69 74 69 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 168 173 168 173 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 274 279 274 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 333 338 333 338 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 404 407 404 407 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M</italic>
Three novel SNPs were identified -764A>G, -714G>T and -649G>A in the NOS3 gene promoter region, which together with the -786T>C generated four haplotypes (N, T, C, A). NOS3 gene expression levels were affected by the -786T>C polymorphism, and there was a 2-fold increase in NOS3 levels favored by the incorporation of each C allele. NOS3 levels higher than 80% of the constitutive gene expression level (B2M) presented a 4-fold increase in PCa occurrence.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 75 80 75 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 223 228 223 228 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 245 250 245 250 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 367 372 367 372 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
The -786T>C polymorphism was the most important promoter alteration of the NOS3 gene that may affect the PCa progression, but not its occurrence, and the incorporation of the C allele is associated with increased levels of NOS3 transcripts. The NOS3 transcript levels presented a bimodal behavior in tumor development and may be used as a biomarker together with the PCA3 marker for molecular staging of the prostate cancer.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 148 149 148 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 181 185 181 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 309 314 309 314 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 685 686 685 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
Enzymes responsible for nitric oxide (NO) synthesis constitute a family with at least three distinct isoforms, inducible, neuronal and endothelial [1]. The nitric oxide synthase 3 (NOS3) is located at the 7q35-q36 chromosome locus and the characterization of the 5'-flanking genomic region indicates that the NOS3 promoter is 'TATA-less'. This feature has been described for genes such as housekeeping genes and is usually associated with multiple transcription start sites. The NO synthase mRNA does not correspond to these criteria and the presence of specific potential transcription factor binding sites in the promoter could account for the cell specificity of its transcription [2].
###end p 11
###begin p 12
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 148 149 148 149 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 305 306 305 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 307 308 307 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 119 124 <span type="species:ncbi:9606">human</span>
The NOS3 seems to have an important role in vascular development, maintenance of the vascular tone and tumor growth in human prostate cancer (PCa) [3]. The net effects of NO depend on its available concentration, target cell, and interactions with reactive oxygen species (ROS), metal ions, and proteins [4,5].
###end p 12
###begin p 13
###xml 152 153 152 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 154 155 154 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 233 234 233 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 290 291 290 291 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 292 294 292 294 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
The tumor-associated NO production may promote cancer progression by providing a selective growth advantage to tumor cells, by the angiogenic stimulus [6,7] and by the raise on mutations due to direct action of free radicals in DNA [8], and may also stimulate hyperplasia in normal tissue [8-10].
###end p 13
###begin p 14
###xml 48 53 48 53 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 66 67 66 67 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
###xml 140 142 140 142 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 143 145 143 145 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 435 440 435 440 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 550 552 550 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
Genetic polymorphisms in the promoter region of NOS3 gene (Figure 1) may be responsible for variations in the genetic control of plasma NO [11,12]. Although the promoter region is not part of the mRNA, it is directly related to the exons, and might be intervening at gene expression, decreasing or increasing it. Moreover, mutation points present in 5'- flanking region may confer a higher instability to the mRNA. To date ten variant NOS3 alleles have been identified in this region, these are, or may be, associated with decreased enzyme activity [13].
###end p 14
###begin p 15
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 0 41 0 41 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Nucleotide sequence of <italic>NOS3 </italic>gene promoter</bold>
Nucleotide sequence of NOS3 gene promoter. Potencial cis-regulatory sequences are indicated in white boxes. The translation iniciation codon ATG is indicated in a black box. Underlined-bold nucleotides are indicating the 13 point mutations described for the promoter region. The three novel mutations and the 236-bp amplified fragment are highlighted in gray boxes.
###end p 15
###begin p 16
###xml 93 98 93 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 532 537 532 537 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 611 619 <span type="species:ncbi:9606">patients</span>
In this study, we have performed a specific analysis of a 236 base pair (bp) fragment of the NOS3 gene promoter region flanking the polymorphisms -786T>C and -690C>T, through DNA conformational assays (SSCP - single strand conformation polymorphism) and sequencing, determining genotypes and haplotypes, and estimating their possible association with PCa and benign prostatic hyperplasia (BPH) diseases. Three novel single nucleotide polymorphisms (SNPs) were characterized. Additionally, we have evaluated the effect of these five NOS3 SNPs on the mRNA expression levels of the peripheral blood of PCa and BPH patients, and their association with circulating tumor cells in the blood.
###end p 16
###begin title 17
Methods
###end title 17
###begin title 18
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients, sample collection and preparation
###end title 18
###begin p 19
###xml 652 654 643 645 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 759 764 744 749 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 1430 1432 1415 1417 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1508 1510 1493 1495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 232 240 <span type="species:ncbi:9606">patients</span>
###xml 836 844 <span type="species:ncbi:9606">patients</span>
###xml 1047 1055 <span type="species:ncbi:9606">patients</span>
###xml 1092 1100 <span type="species:ncbi:9606">patients</span>
###xml 1149 1157 <span type="species:ncbi:9606">patients</span>
This work was developed at the Laboratory of Nanobiotechnology of the Federal University of Uberlandia (UFU) together with the Urology Service of the University Clinics' Hospital. All the peripheral blood samples were obtained from patients that live in Uberlandia - MG (Brazil) and were enrolled during 2003 and 2004. The ethnic background was not recorded since the Brazilian population is highly heterogeneous and miscegenated, so it cannot be determined. The investigation was approved by the UFU Research Ethics Committee under the number 005/2001. Peripheral blood samples were collected before surgery in a vacutainertrade mark tube containing K2 EDTA 7.2 mg, and maintained at 4degreesC. To search for possible mutations in the promoter region of the NOS3 gene, we have performed the PCR-SSCP analysis in blood samples from 177 patients, which were grouped into two classes: 83 PCa (mean age, 69 years; range, 50 to 87 years) and 94 BPH (mean age, 68 years; range, 49 to 87 years), according to histological classification of tissues. BPH patients were submitted to TURP, except five patients that have undergone open prostatectomy. All PCa patients were submitted to radical prostatectomy, and were selected by using the following criteria: negative X-rays and bone scan analyses, and rectal examination compatible with organ confined cancer. DNA was extracted from leukocytes according to protocol previously published [14]. The mRNA was isolated by the Guanidine Isothiocyanate extraction method [15] with minor modifications. DNA and mRNA concentrations and quality were obtained by using the spectrophotometric absorbance readings at 260 and 280 nm.
###end p 19
###begin title 20
Amplification and genotyping of the -786T>C polymorphism
###end title 20
###begin p 21
###xml 75 80 75 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 214 216 214 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 386 387 382 383 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
The presence of the -786T>C polymorphism in the 5'- flanking region of the NOS3 gene was determined by PCR amplification with the primers 5'-ATG CTG CCA CCA GGG CAT CA- 3' and 3'-GTC CTT GAC TCT GAC ATT AGG G- 5' [16]. A volume of 30 muL was used for each PCR reaction, which contained 5 rhomoles of each primer, 200 muM of each dNTP (desoxyribonucleotide triphosphate), 1.5 mmol/L MgCl2, 50 mmol/L KCl, 10 mmol/L Tris-HCl at pH 8.3 and 1 U Taq DNA polymerase (Phoneutria) with 4 muL of genomic DNA. The conditions of amplification were denaturing at 95degreesC-5 min, 35 cycles at 94degreesC-1 min, 62degreesC-1 min, 72degreesC-1 min, and a finally termination at 72degreesC-10 min. The amplified fragments were separated on 1.5% agarose gel electrophoresis and stained with ethidium bromide.
###end p 21
###begin title 22
PCR-SSCP analysis
###end title 22
###begin p 23
###xml 42 44 42 44 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 92 97 92 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 498 500 491 493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 501 503 494 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
A PCR-SSCP analysis, described elsewhere [17], was performed to detect mutations within the NOS3 promoter region. Two microliters of PCR products were mixed with 18 muL of a low ionic strength buffer (10% sucrose, 0.01% bromophenol blue, and 0.01% xylene cyanol) and heat-denatured for 10 min at 97degreesC. Products were separated on 15% polyacrylamide gel electrophoresis (49:1 - acrylamide:bisacrylamide) with 200 volts for 19 hours at room temperature, and detected by silver nitrate staining [18,19] with minor modifications.
###end p 23
###begin title 24
Purification of SSCP fragment bands and sequencing
###end title 24
###begin p 25
###xml 53 58 53 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 415 416 415 416 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
During genotyping of the -786T>C polymorphism of the NOS3 gene promoter region, three novel SNPs have been discovered [-764A>G, GenBank: RefSeq /-714G>T, GenBank: RefSeq /-649G>A, GenBank: RefSeq ]. Additionally, the two SNPs previously described [-786T>C, GenBank: RefSeq /-690C>T, GenBank: RefSeq ] were also characterized. Seven SSCP conformations were observed in the polyacrylamide gel electrophoresis (Figure 2), although only three conformations were expected.
###end p 25
###begin p 26
###xml 0 17 0 17 <bold xmlns:xlink="http://www.w3.org/1999/xlink">PCR-SSCP analysis</bold>
###xml 246 251 246 251 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
PCR-SSCP analysis. 15% polyacrylamide gel electrophoresis (49:1 acrylamide:bisacrylamide) with silver staining, evidencing the seven genotypic conformations and their chromosome models with four possible haplotypes, constructed based on the five NOS3 promoter polymorphisms investigated.
###end p 26
###begin p 27
Each DNA fragment band originated from the PCR-SSCP technique was scrapped and individually reamplified using the same PCR reaction condition.
###end p 27
###begin p 28
The purification of reamplified fragments was performed by DNA precipitation with ammonium acetate (7.5 M) and the pellet was ressuspended in 10 muL of water. DNA concentration and quality were obtained by using the spectrophotometric absorbance readings at 260 and 280 nm.
###end p 28
###begin p 29
###xml 429 434 429 434 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 626 631 626 631 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
The purified products were submitted to a capillary sequencer (MegaBace 1000), using the DYEnamic ET Dye Terminator Cycle Sequencing kit (GE Healthcare). Three sequencing reactions had been carried for each fragment and injected twice to minimize sequencing artifacts. Sequences were processed and edited in the software DNASTAR Lasergene - SeqMan and EditSeq - (version 7.0, 2006). Sequences were aligned with the corresponding NOS3 sequence (GenBank: ) using the MegAlign procedure (DNASTAR Lasergene). The consensus sequences for each SSCP fragment band was established and comparisons were performed based on the original NOS3 gene sequence.
###end p 29
###begin title 30
RNA extraction and RT-PCR
###end title 30
###begin p 31
###xml 91 121 91 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Murine Moloney Leukemia Virus </italic>
###xml 527 531 512 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M </italic>
###xml 537 540 522 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M</italic>
###xml 91 97 <span type="species:ncbi:10090">Murine</span>
Two microgramas of total RNA from blood, 10 U of RNase inhibitor (Invitrogen), 40 U of the Murine Moloney Leukemia Virus Reverse Transcriptase (MMLV-RT) (Amersham Biosciences), 1X MMLV-RT Buffer, 200 muM of each dNTP and 6 muM of hexamer random primers were incubated at 37degreesC for 1 hour and heated at 95degreesC-5 min. The 20 muL final volume of each reaction was completed with DEPC (diethylpyrocarbonate)-treated water. For normalization of amplification reactions, the internal positive control gene, the constitutive B2M gene (B2M: 5' -AGC AGA GAA TGG AAA GTC AAA- 3' and 5' -TGT TGA TGT TGG ATA AGA GAA- 3'), generating a 534-bp fragment, was used to validate reactions and to further characterize RNA quality of each sample.
###end p 31
###begin title 32
###xml 22 27 22 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
Nested RT-PCR for the PCA3 transcript detection
###end title 32
###begin p 33
###xml 50 55 50 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 257 262 257 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 297 299 297 299 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 304 306 304 306 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 143 151 <span type="species:ncbi:9606">patients</span>
A sensitive nested PCR assay for the detection of PCA3 mRNA was performed as previously reported [20] with minor modifications. A total of 137 patients were analyzed for the expression of circulating tumor cells in the peripheral blood, as evidenced by the PCA3 tumor biomarker positivity (Figure 3A and 3B).
###end p 33
###begin p 34
###xml 22 27 22 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 31 35 31 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M </italic>
###xml 0 59 0 59 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Nested RT-PCR for the <italic>PCA3 </italic>and <italic>B2M </italic>gene expression analysis</bold>
###xml 101 106 101 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 248 253 248 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 381 382 381 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 383 385 383 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M </italic>
###xml 433 438 433 438 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 442 443 442 443 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 444 446 444 446 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M </italic>
###xml 522 527 522 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 531 532 531 532 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B</italic>
###xml 533 535 533 535 <italic xmlns:xlink="http://www.w3.org/1999/xlink">M </italic>
###xml 202 209 <span type="species:ncbi:9606">patient</span>
###xml 619 627 <span type="species:ncbi:9606">patients</span>
###xml 653 661 <span type="species:ncbi:9606">patients</span>
###xml 688 696 <span type="species:ncbi:9606">patients</span>
Nested RT-PCR for the PCA3 and B2M gene expression analysis. A) Lanes 1 to 4: amplifications for the PCA3 gene, where sample pairs 1 and 2, 3 and 4, correspond to two RNA extraction replicates for each patient. The detection of the expected 277-bp PCA3 fragment evidences the presence of circulating tumor cells. Lane M: 100-bp size marker. B) Lanes 1 to 4: amplifications for the B2M gene (534-bp). Semi-quantitative RT-PCR for the NOS3 and B2M gene expression analysis. The 322-bp and 534-bp fragments correspond to the NOS3 and B2M genes, respectively. Lane M: 100-bp size marker. Lanes 1 to 10 represent individual patients, where (C) represent BPH patients' profile, and (D) the PCa patients' profile.
###end p 34
###begin title 35
###xml 32 37 32 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
Semi-quantitative RT-PCR of the NOS3 gene
###end title 35
###begin p 36
###xml 165 170 165 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 411 412 407 408 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 653 658 619 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 789 793 755 759 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M </italic>
###xml 83 91 <span type="species:ncbi:9606">patients</span>
A representative sample of the genotyped population was selected, consisting of 38 patients (18 PCa and 20 BPH cases), and were analyzed in three replicates for the NOS3 mRNA relative expression levels. PCR reactions consisted of: 4 muL of cDNA, 1 U of Platinum Taq DNA Polymerase (Invitrogen), 50 mmol/L KCl, 10 mmol/L Tris-HCl at pH 8.3, 200 muM of each dNTP, 8 rhomoles of each oligonucleotide, 2 mmol/L MgCl2. The reaction was incubated for 48 cycles at 94degreesC-40 s, 55degreesC-40 s, 72degreesC-50 s, preceded by an initial denaturation at 95degreesC-2 min and a final extension cycle at 72degreesC-10 min. The designed primers sequence for the NOS3 were: sense 5' -CCT CAG GTT CTG TGT GTT CG- 3' and antisense 5'- GAT CAG ACCT GGC AGC AAC T- 3', generating a 322-bp fragment. The B2M constitutive gene was concomitantly amplified in the same reaction as described before.
###end p 36
###begin title 37
Densitometric readings to estimate relative gene expression levels
###end title 37
###begin p 38
###xml 32 37 32 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 41 45 41 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M </italic>
###xml 271 276 271 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 281 285 281 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M </italic>
###xml 355 357 355 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3C</xref>
###xml 362 364 362 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3D</xref>
The amplicons obtained for both NOS3 and B2M genes were analyzed and quantified according to their agarose signal intensities by using the ImageMaster VDS Software program version 2.0 (Amersham Biosciences). The densitometric readings were normalized by using the target NOS3 mRNA:B2M mRNA ratio and relative levels were estimated for each sample (Figure 3C and 3D).
###end p 38
###begin title 39
Statistical analysis
###end title 39
###begin p 40
###xml 264 269 264 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 375 380 375 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 636 641 636 641 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 775 780 775 780 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 844 849 844 849 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 481 489 <span type="species:ncbi:9606">patients</span>
###xml 891 899 <span type="species:ncbi:9606">patients</span>
###xml 920 928 <span type="species:ncbi:9606">patients</span>
Chi-square analyses were performed to compare genotypic and haplotypic frequencies for the average of clinical parameters, such as: age, PSA serum levels. Multiple regression analysis and Pearsons' correlations were used to verify the association among genotypes, PCA3 detection and clinical data. The Shapiro-Wilk test was used to verify normality of the relative levels of NOS3 gene expression, and mean comparisons of the mRNA relative levels were performed between PCa and BPH patients' groups through the Mann-Whitney test. Probability levels below 5% (p < 0.05) were considered significant. A cut-off value was determined for the NOS3 transcript relative levels and the OR were estimated to verify the chance of PCa occurrence in the presence of high concentrations of NOS3 transcripts. Pearsons' correlation analysis was performed among NOS3 relative expression levels of PCa and BPH patients in association with patients' age, serum PSA levels, the TNM adenocarcinoma histopathological staging, gleason score and polymorphisms.
###end p 40
###begin title 41
Results
###end title 41
###begin title 42
Molecular characterization of the SSCP conformations and the haplotypes models of the promoter region
###end title 42
###begin p 43
###xml 109 110 109 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
###xml 181 186 181 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 306 307 306 307 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
Sequences of the SSCP electrophoretic bands were obtained and the consensus sequence was established (Figure 4). Sequence alignments were compared with the original sequence of the NOS3 gene [GenBank: ], and all SNPs were positioned in the sequence, and their mutation classifications were assigned (Table 1).
###end p 43
###begin p 44
###xml 0 84 0 84 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Sequences alignment using DNASTAR Lasergene (SEQMAN and EDITSEQ), version 7.0 (2006)</bold>
###xml 292 297 292 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
Sequences alignment using DNASTAR Lasergene (SEQMAN and EDITSEQ), version 7.0 (2006). The point mutations are represented in a black box. A) -786T>C polymorphism. B) -764A>G polymorphism. C) -714G>T polymorphism. D) -690C>T polymorphism. E) -649G>A. Coding DNA reference sequence of promoter NOS3 gene [GenBank: ]. SSCP Conformations: AA, CC, TN, TA and TT.
###end p 44
###begin p 45
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
NOS3 gene promoter point mutations according to site and type.
###end p 45
###begin p 46
###xml 0 4 0 4 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(&#359;) </bold>
(t) novel single nucleotide polymorphism
###end p 46
###begin p 47
###xml 0 5 0 5 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(--) </bold>
(--) polymorphism located outside the 236-bp
###end p 47
###begin p 48
###xml 0 4 0 4 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(W) </bold>
###xml 12 15 12 15 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(S)</bold>
###xml 23 26 23 26 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(V)</bold>
###xml 39 42 39 42 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(R)</bold>
###xml 50 53 50 53 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(Y)</bold>
###xml 61 64 61 64 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(N)</bold>
###xml 74 77 74 77 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(K)</bold>
(W) A or T; (S)G or C; (V)A or C ou G; (R)A or G; (Y)C or T; (N)any base; (K)G or T.
###end p 48
###begin p 49
###xml 669 670 669 670 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2</xref>
Based on consensus sequences, it was possible to construct four specific haplotypes N (-786T>C; -690A>G; -649G>A), C (-786T>C; -714G>T; -690C>T), A (-786 T>C; -764A>G; -690C>T) and T (no mutations). Chromosome models were also generated to explain the seven SSCP electrophoretic conformations: TT (no mutations), TC (-786T>C + [=], -714G>T + [=], -690C>T + [=]), CC (-786T>C + -786T>C, -714G>T + -714G>T, -690C>T + -690C>T), TA (-786T>C + [=], -764A>G + [=], -690C>T + [=]), AA (-786T>C + -786T>C, -764A>G + -764A>G, -690C>T + -690C>T), CA (-786T>C + -786T>C, -764A>G + [=], -714G>T + [=], -690C>T + -690C>T and TN (-786T>C + [=], -690C>T + [=], -649G>A + [=]) (Figure 2).
###end p 49
###begin title 50
###xml 90 95 90 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
SSCP conformations and haplotypic frequencies of the five mutations in promoter region of NOS3 gene
###end title 50
###begin p 51
###xml 6 7 6 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 150 158 <span type="species:ncbi:9606">patients</span>
###xml 309 317 <span type="species:ncbi:9606">patients</span>
Table 2 shows SSCP conformations with their respective genotypes and haplotypic frequencies for all five characterized polymorphisms performed in 177 patients, from which 83 (46.9%) were histologically diagnosed as PCa and 94 (53.1%) as BPH. The -786T>C polymorphism presented the highest frequencies in both patients' groups, with higher frequencies for the TT and TC SSCP conformations. For the PCa group, all the other conformations (TA, CA, TN, and AA) did not present frequencies higher than 6%; however, the same four genotypic conformations presented higher frequencies in the BPH group, with 13.8% (13 out of 94) for the TA SSCP conformation, and 9.6% (9 out of 94) for the CA SSCP conformation.
###end p 51
###begin p 52
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SSCP </italic>
###xml 93 98 93 98 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 126 134 <span type="species:ncbi:9606">patients</span>
SSCP conformation and haplotypic frequencies, clinical parameters and laboratory data of the NOS3 gene in peripheral blood of patients with prostate cancer and benign prostatic hyperplasia.
###end p 52
###begin p 53
(t) representative sampling of the population; (*) mean (+/- SD); (--) inapplicable data
###end p 53
###begin p 54
(1) Comparison (genotypes) in the groups with probability levels obtained by chi-square tests
###end p 54
###begin p 55
(2) Comparison (genotypes) between groups with probability levels obtained by Kruskal-Wallis test
###end p 55
###begin p 56
(a) Genotypes correspond to the promoter NOS3 polymorphisms
###end p 56
###begin p 57
###xml 70 78 <span type="species:ncbi:9606">patients</span>
###xml 190 198 <span type="species:ncbi:9606">patients</span>
###xml 227 235 <span type="species:ncbi:9606">patients</span>
No significant differences for SSCP conformations frequencies between patients' groups were observed (p = 0.10). However, the comparison of the SSCP conformations frequencies within the PCa patients (p = 0.0082) and within BPH patients (p = 0.0011) were significant different.
###end p 57
###begin p 58
###xml 218 226 <span type="species:ncbi:9606">patients</span>
###xml 310 318 <span type="species:ncbi:9606">patients</span>
###xml 423 431 <span type="species:ncbi:9606">patients</span>
There was no haplotypic frequencies difference between groups (p > 0.05). However, inspection of haplotypes revealed that the C (-786T>C; -714G>T; -690C>T) and T (no mutation) haplotype was the most common one in both patients' groups. One rare haplotype N (-786T>C; -690A>G; -649G>A) has been observed in PCa patients (1.2%). Although not significant, the haplotype A (-786 T>C; -764A>G; -690C>T) was more frequent in BPH patients (12%) than in PCa (8%). Both haplotypes and SSCP genotypic conformation frequencies distribution were in Hardy-Weinberg equilibrium.
###end p 58
###begin p 59
###xml 152 159 152 159 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus </italic>
###xml 160 163 160 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vrs</italic>
###xml 195 198 195 198 <sub xmlns:xlink="http://www.w3.org/1999/xlink">95%</sub>
###xml 223 227 223 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vrs </italic>
###xml 243 246 243 246 <sub xmlns:xlink="http://www.w3.org/1999/xlink">95%</sub>
###xml 266 270 266 270 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vrs </italic>
###xml 291 294 291 294 <sub xmlns:xlink="http://www.w3.org/1999/xlink">95%</sub>
###xml 314 318 314 318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vrs </italic>
###xml 339 342 339 342 <sub xmlns:xlink="http://www.w3.org/1999/xlink">95%</sub>
###xml 738 742 738 742 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vrs </italic>
###xml 757 761 757 761 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vrs </italic>
The estimated chance for cancer occurrence, considering the seven SSCP genotypic conformations among groups (PCa and BPH), were: TT + TC + CC + CA + AA versus (vrs) TA (odds ratio (OR) = 3.13, CI95%, 0.98 - 10.01), TT + CA vrs TA (OR= 2.99, CI95%, 0.89 - 10.05), CC vrs CA + TA (OR= 3.38, CI95%, 1.00 - 11.37), TT vrs CA + TA (OR= 3.10, CI95%, 1.25 - 7.72). All combinations of SSCP conformations were tested for the OR, but only the most significant ones were demonstrated. It was observed a 3.38-fold higher chance of having cancer when the CC SSCP conformation is considered in relation to CA + TA. A 3.10-fold higher chance of having cancer was obtained for the TT SSCP conformation in relation to CA + TA. The TT + TC + CC + CA + AA vrs TA and TT + CA vrs TA associations were close to significance (p < 0.10), and presented a relative risk of 3.13 and 2.99-fold higher chance of having cancer, respectively.
###end p 59
###begin p 60
###xml 6 7 6 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 513 518 513 518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
Table 3 shows the estimated chance for cancer occurrence, considering haplotypes and their number of copies between groups (PCa and BPH), and no significant ORs were obtained. The sample size was quite small for some haplotypes, but we presented the true haplotypic frequencies of copy numbers in the population investigated for the polymorphisms within the 236-bp region, and although the haplotypes were not significantly associated with prostate cancer, this is the first description of such variations in the NOS3 promoter.
###end p 60
###begin p 61
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
NOS3 gene promoter haplotypes, number of copies, and prostate cancer risk.
###end p 61
###begin p 62
(a) Alleles listed for dbSNP ID (GenBank) in 5' to 3' order: , , , , .
###end p 62
###begin p 63
(b) Haplotype that appear only once between groups (PCa and BPH).
###end p 63
###begin p 64
CI: confidence interval/OR: odds ratio
###end p 64
###begin p 65
(--) inapplicable data
###end p 65
###begin p 66
###xml 210 214 210 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vrs </italic>
###xml 240 244 240 244 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vrs </italic>
###xml 276 280 276 280 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vrs </italic>
###xml 302 306 302 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vrs </italic>
###xml 348 352 348 352 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vrs </italic>
###xml 407 411 407 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vrs </italic>
###xml 555 556 555 556 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 75 83 <span type="species:ncbi:9606">patients</span>
###xml 449 457 <span type="species:ncbi:9606">patients</span>
###xml 525 533 <span type="species:ncbi:9606">patients</span>
In agreement with the Kruskal-Wallis test, significant differences between patients' groups for mean prostate specific antigen (PSA) were observed (p = 0.0048). Pearsons' correlation coefficients for genotypes vrs PSA (p = 0.02), genotypes vrs gleason score (p = 0.0195), age vrs PSA (p = 0.0412), age vrs gleason score (p = 0.0421), gleason score vrs Tumor-Node-Metastasis (TNM) score (p = 0.0021) and PSA vrs TNM score (p = 0.0189) within the PCa patients were significantly different. No significant differences among BPH patients were observed (Table 2).
###end p 66
###begin title 67
###xml 16 21 16 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
Analysis of the PCA3 transcript detection and association with polymorphisms
###end title 67
###begin p 68
###xml 31 35 31 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3</italic>
###xml 66 68 66 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3A</xref>
###xml 191 196 191 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 312 317 312 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 409 410 409 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 91 99 <span type="species:ncbi:9606">patients</span>
###xml 205 213 <span type="species:ncbi:9606">patients</span>
###xml 326 334 <span type="species:ncbi:9606">patients</span>
###xml 422 430 <span type="species:ncbi:9606">patients</span>
###xml 578 586 <span type="species:ncbi:9606">patients</span>
The prostate cancer antigen 3 (PCA3) transcript detection (Figure 3A) was performed in 149 patients (149 out of 177), from which 109 (73.2%) were negative and 40 (26.8%) were positive. Among PCA3 positive patients, 62.5% (25 out of 40) were histologically diagnosed as PCa and 37.5% (15 out of 40) as BPH. Among PCA3 negative patients, 42.2% (46 out of 109) were PCa and 57.8% (63 out of 109) were BPH (Table 4). Although patients' histological classification (PCa and BPH) were carefully analyzed, it is possible that transurethral resection of prostate (TURP) biopsies of BPH patients have been misdiagnosed, once biopsy procedures may not have reached tumor specific sites.
###end p 68
###begin p 69
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 59 67 <span type="species:ncbi:9606">patients</span>
PCA3 mRNA detection in the peripheral blood of PCa and BPH patients across genotypic SSCP conformations and their haplotypes.
###end p 69
###begin p 70
###xml 2 7 2 7 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
* PCA3 gene expression (PCa = 71/BPH = 78)
###end p 70
###begin p 71
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 82 83 82 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 123 128 123 128 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 287 292 287 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 423 427 423 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vrs </italic>
###xml 569 573 569 573 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vrs </italic>
###xml 606 611 606 611 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 634 635 634 635 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 773 778 773 778 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 539 547 <span type="species:ncbi:9606">patients</span>
PCA3 positivity in all SSCP conformations and haplotypes were also shown in Table 4. It was expected a higher frequency of PCA3 positivity in the PCa group and a lower frequency of positivity in the BPH group, as observed, although not significant. It is interesting to mention that the PCA3 positivity in the PCa group for the TC + CC conformations was 2.6 times higher than the frequency observed in the BPH group (32.5% vrs 12.5%, P = 0.02). On the other hand, CC + TC conformations frequencies were not significantly different between patients' groups (PCa = 20.2% vrs BPH = 26.6%) within the negative PCA3 detection class (Table 4). The TA + CA conformations presented significantly higher frequencies in the BPH (11%) than in the PCa group (3.6%) within the negative PCA3 class (P = 0.03).
###end p 71
###begin p 72
###xml 20 25 20 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 298 303 298 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 245 253 <span type="species:ncbi:9606">patients</span>
###xml 320 328 <span type="species:ncbi:9606">patients</span>
In the overall, the PCA3 clinical parameters for PCa cell detection in the peripheral blood were: 35.0% of sensitivity (25 out of 71), and 81.0% of specificity (63 out of 78); however, it is important to emphasize that a positive result for PCa patients is not an indication of metastasis, and the PCA3 detection in BPH patients may indicate that they may have been misdiagnosed.
###end p 72
###begin p 73
###xml 17 22 17 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 39 40 39 40 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 91 99 <span type="species:ncbi:9606">patients</span>
###xml 187 194 <span type="species:ncbi:9606">patient</span>
For the negative PCA3 detection (Table 4), all genotypic frequencies were higher among BPH patients, except for the TN SSCP conformation that presented only a negative result for one PCa patient.
###end p 73
###begin p 74
###xml 69 74 69 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 398 403 398 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 127 135 <span type="species:ncbi:9606">patients</span>
###xml 357 365 <span type="species:ncbi:9606">patients</span>
Considering the haplotypic frequencies for the positive and negative PCA3 detection classes, there were no differences between patients' groups. However, the T haplotype (no mutations) was the most frequent one followed by the C (-786T>C; -714G>T; -690C>T) and A (-786 T>C; -764A>G; -690C>T) haplotypes. The A haplotype was more frequent in BPH than in PCa patients, for both positive and negative PCA3 classes, although it was not significant.
###end p 74
###begin title 75
###xml 16 21 16 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
Analysis of the NOS3 gene expression levels in association with polymorphisms
###end title 75
###begin p 76
###xml 38 43 38 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 254 262 <span type="species:ncbi:9606">patients</span>
###xml 386 394 <span type="species:ncbi:9606">patients</span>
###xml 412 420 <span type="species:ncbi:9606">patients</span>
The semi-quantitative analyses of the NOS3 transcript levels and their association with polymorphisms and haplotypes were performed by selecting a representative sample of the population based on the genotypic frequencies and clinical parameters. The 38 patients used in this study presented the same genotypic frequencies and average values for the clinical parameters observed in the patients' population (177 patients).
###end p 76
###begin p 77
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 62 65 62 65 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M</italic>
###xml 183 188 183 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 268 273 268 273 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 278 282 278 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M </italic>
###xml 325 327 325 327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3B</xref>
###xml 252 260 <span type="species:ncbi:9606">patients</span>
The NOS3 relative levels related to the beta-2-microglobulin (B2M) in the peripheral blood did not follow a normal distribution (n = 38, p = 0.33). Although not significant, the mean NOS3 relative levels was four times higher in PCa in relation to BPH patients (ratio NOS3 mRNA/B2M mRNA: 2.23 and 0.50, respectively) (Figure 3B).
###end p 77
###begin p 78
###xml 43 48 43 48 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 202 207 202 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 212 216 212 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M </italic>
###xml 274 278 274 278 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M </italic>
###xml 372 375 372 375 <sub xmlns:xlink="http://www.w3.org/1999/xlink">95%</sub>
###xml 427 432 427 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
A cut-off value for the relative levels of NOS3 transcripts were established based on the maximum average levels observed for the BPH group. The cut-off value for negative results was below 0.8 for the NOS3 mRNA/B2M mRNA ratio, which means 80% of the observed value for the B2M transcript levels. Considering the cut-off value, it was observed a 4.0-fold higher chance (CI95%, 0.95 - 16.77; p = 0.12) of having cancer when the NOS3 expression levels were equal or higher than 0.8.
###end p 78
###begin p 79
###xml 83 88 83 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 108 113 108 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 170 175 170 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 225 230 225 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 299 304 299 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 444 446 444 446 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
###xml 10 18 <span type="species:ncbi:9606">patients</span>
###xml 156 164 <span type="species:ncbi:9606">patients</span>
###xml 194 202 <span type="species:ncbi:9606">patients</span>
###xml 347 355 <span type="species:ncbi:9606">patients</span>
Among PCa patients, only the Pearsons' correlation coefficients obtained among the NOS3 gene expression and PCA3 data (p = 0.038) were significant. For BPH patients, the NOS3 levels, serum PSA, patients' age on diagnosis and PCA3 detection were not correlated among each other. However, the average NOS3 levels presented a bimodal behavior in PCa patients classified according to their tumor stages, with higher levels in the pT2 stage (Figure 5A).
###end p 79
###begin p 80
###xml 0 24 0 24 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Graphics representations</bold>
###xml 41 46 41 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 185 190 185 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 322 327 322 327 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 69 77 <span type="species:ncbi:9606">patients</span>
###xml 269 277 <span type="species:ncbi:9606">patients</span>
###xml 299 307 <span type="species:ncbi:9606">patients</span>
Graphics representations. A) The average NOS3 relative levels of PCa patients classified according to tumor stages and a predicted tendency line. B) Regression analysis for the average NOS3 relative levels in association with the -786T>C polymorphism genotypes for all patients and for the group of patients with positive PCA3 detection.
###end p 80
###begin p 81
###xml 33 38 33 38 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 112 113 112 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 164 169 164 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 302 307 302 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 405 410 405 410 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 415 419 415 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M </italic>
###xml 214 222 <span type="species:ncbi:9606">patients</span>
###xml 356 364 <span type="species:ncbi:9606">patients</span>
No significant differences among NOS3 gene expression levels and haplotypes were observed between groups (Table 2). However, there was a significant association of NOS3 genotypes and gene expression levels for PCa patients (p = 0.011), but not within the BPH group. It was observed increased levels of NOS3 transcripts within the PCa group, especially for patients with TA and CA SSCP conformations, with NOS3 mRNA/B2M mRNA ratios of 4.7 and 6.0, respectively.
###end p 81
###begin p 82
###xml 12 17 12 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 49 54 49 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 73 78 73 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 83 87 83 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M </italic>
###xml 141 146 141 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 165 170 165 170 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 175 179 175 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M </italic>
###xml 244 249 244 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 63 71 <span type="species:ncbi:9606">patients</span>
###xml 155 163 <span type="species:ncbi:9606">patients</span>
The average NOS3 levels were 3.52-fold higher in PCA3 positive patients (NOS3 mRNA/B2M mRNA = 3.17) in comparison to the average observed in PCA3 negative patients (NOS3 mRNA/B2M mRNA = 0.90), although not significant, due to the low number of PCA3 positive samples analyzed.
###end p 82
###begin p 83
###xml 16 21 16 21 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 413 415 413 415 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
###xml 78 86 <span type="species:ncbi:9606">patients</span>
###xml 270 278 <span type="species:ncbi:9606">patients</span>
###xml 396 404 <span type="species:ncbi:9606">patients</span>
Analysis of the NOS3 expression levels across the -786T>C polymorphism on all patients showed a linear behavior with an additive component for each C allele incorporated into the genotype, with higher levels (2.27) observed for the (-786T>C + -786T>C) mutant homozygous patients, followed by medium levels (1.47) for the (-786T>C + [=]) heterozygous and lower levels (0.67) for normal homozygous patients (Figure 5B).
###end p 83
###begin p 84
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 47 52 47 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 368 370 368 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
###xml 80 88 <span type="species:ncbi:9606">patients</span>
###xml 227 235 <span type="species:ncbi:9606">patients</span>
###xml 351 359 <span type="species:ncbi:9606">patients</span>
Similarly, the NOS3 levels within the positive PCA3 class (grouping BPH and PCa patients) presented a linear behavior considering the -786T>C polymorphism, with higher levels (3.1) for the (-786T>C + -786T>C) mutant homozygous patients, followed by medium levels (2.3) for the (-786T>C + [=]) heterozygous and lower levels (1.5) for normal homozygous patients (Figure 5B).
###end p 84
###begin title 85
Discussion
###end title 85
###begin p 86
###xml 57 62 57 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 72 74 72 74 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 214 222 <span type="species:ncbi:9606">patients</span>
During the genotyping of the -786T>C polymorphism of the NOS3 promoter [16], we have discovered and characterized three novel mutations [-764A>G, GenBank: /-714G>T, GenBank: /-649G>A, GenBank: ] in the PCa and BPH patients. The association between these three mutations together with two SNPs previously described [-786T>C, GenBank: /-690C>T, GenBank: ] and prostate cancer was further examined.
###end p 86
###begin p 87
The five polymorphisms have generated seven genotypic profiles in the polymerase chain reaction-single-strand conformation polymorphism (PCR-SSCP) gel electrophoresis and four haplotypes, suggesting that some mutations are closely linked; therefore, they have evolved together, originating a restricted number of haplotypes. It is interesting to observe that when the -786T>C mutation was present at least two other mutations were linked. But, when the normal -786T allele was present, no additional polymorphisms were detected, explaining the four possible haplotypes.
###end p 87
###begin p 88
###xml 80 85 80 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 224 226 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
This is the first publication that associates the promoter polymorphisms of the NOS3 gene with prostate cancer risk; however, other polymorphisms, such as the 894G>T (Glu298Asp) and the intron 4 have also been evaluated [21-24].
###end p 88
###begin p 89
###xml 64 69 64 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 412 417 412 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 521 526 521 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 577 582 577 582 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 593 595 593 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
The possibility of linkage between the two previously described NOS3 gene polymorphisms and the promoter polymorphisms has not been investigated, and some controversies may occur in the literature probably due to the incorrect population stratification based on genotyping, which could be generating linkage disequilibrium among polymorphisms in the population that may present a functional association with the NOS3 expression and activity. However, there is an evidence that the 894G>T polymorphism had no influence on NOS3 transcriptional levels, but it was associated with PCA3 detection [24].
###end p 89
###begin p 90
###xml 59 64 59 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 160 168 <span type="species:ncbi:9606">patients</span>
###xml 470 478 <span type="species:ncbi:9606">patients</span>
The strategy of determining genotypic conformations of the NOS3 promoter region through the SSCP technique demonstrated to be very effective in classifying all patients. The significant relative risks of cancer occurrence related to CC and TT SSCP conformation (3.38 and 3.10, respectively) in comparison to TA + CA suggest that the -786T>C polymorphism is the most important promoter alteration that may affect the PCa progression. It is also important to observe that patients with the CC SSCP conformation, in both PCa and BPH groups, presented the highest serum PSA averages.
###end p 90
###begin p 91
###xml 88 93 88 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 195 200 195 200 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 341 346 341 346 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 381 386 381 386 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 420 425 420 425 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 528 533 528 533 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 612 614 612 614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 615 617 615 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 386 394 <span type="species:ncbi:9606">patients</span>
In the present work, there is a good evidence that the -786T>C polymorphism affects the NOS3 expression, with the (-786T>C + -786T>C) mutant homozygous condition presenting the highest levels of NOS3 transcripts, and acting in an additive manner, as the C allele is incorporated into the genotype. This was also observed within the positive PCA3 detection class, although positive PCA3 patients present higher levels of NOS3 transcripts. However, some authors have associated the (-786T>C + -786T>C) genotype with low levels of NOS3 mRNA, which would be contributing to a higher risk of cardiovascular diseases [25-27].
###end p 91
###begin p 92
###xml 58 63 58 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 146 151 146 151 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 159 163 159 163 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 164 168 164 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M </italic>
###xml 237 242 237 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 337 342 337 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 370 375 370 375 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 418 420 418 420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5B</xref>
###xml 426 431 426 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 512 514 512 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F5">5A</xref>
The association of the -786T>C promoter polymorphism with NOS3 transcriptional levels and the highly significant odds ratio (4-fold) for elevated NOS3 levels (NOS3:B2M > 0.8) and the risk of PCa occurrence are important evidences of the NOS3 gene promoter role in the PCa progression. This is further supported by the 2-fold increase in NOS3 mRNA levels in the positive PCA3 detection class, as demonstrated in Figure 5B. The NOS3 transcriptional activity was also highly correlated with disease staging (Figure 5A), once its highest level is reached at the pT2 stage, when the angiogenic stimulus is required for tumor cell dissemination and metastasis.
###end p 92
###begin p 93
###xml 104 106 104 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 107 109 107 109 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 162 164 162 164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 198 203 198 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
Recent studies have described the NO involvement in many biological processes affecting carcinogenesis [28-31]. Our results are also supported by previous works [24], which have also indicated that NOS3 levels may present a bimodal behavior during cancer development.
###end p 93
###begin p 94
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 229 234 229 234 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 310 315 310 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
The fine mapping of the NOS3 promoter region, flanking the region -820 to -583, has allowed us to construct four haplotypes and seven genotypic combinations. We have found that none of the haplotypes did affect significantly the NOS3 levels; in fact, a unique polymorphism (-786T>C) may be responsible for the NOS3 transcription regulation, and this polymorphism is observed only in haplotypes N, C and A.
###end p 94
###begin p 95
###xml 15 20 15 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 202 203 202 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 204 205 204 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 262 263 262 263 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 263 265 263 265 <sup xmlns:xlink="http://www.w3.org/1999/xlink">- </sup>
###xml 322 323 322 323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
The increasing NOS3 expression levels associated with the -786T>C polymorphism may contribute to cancer progression by providing a selective growth advantage of tumor cells, by the angiogenic stimulus [6,7] and by causing DNA damage due to the direct action of O2- free radicals, as an effect of the excess NO production [8].
###end p 95
###begin p 96
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 165 167 165 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 225 230 225 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 310 312 310 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
The suggestion that decreasing NOS3 expression levels, which consequently reduce the NO production, would have an anti-apoptotic role, and may promote tumor growth [32] may be explained in part by the bimodal behavior of the NOS3 levels across the stages as shown in this investigation and in a previous work [24], once lower levels is mainly seen in advanced tumor stages (pT3 and pT4).
###end p 96
###begin p 97
###xml 41 46 41 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 203 208 203 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FOLH1</italic>
###xml 246 248 246 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 279 287 <span type="species:ncbi:9606">patients</span>
The first evidence of the association of NOS3 polymorphisms with circulating tumor cells was demonstrated between the intron 4 polymorphism and the folate hydrolase - prostate-specific membrane antigen (FOLH1) expression in the peripheral blood [23]. According to these authors, patients with the 'a' allele have low plasmatic NO levels, and therefore are more inclined to have viable circulating tumor cells.
###end p 97
###begin p 98
###xml 63 68 63 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 125 130 125 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 221 226 221 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 237 239 237 239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
In this investigation, we did not find association between the NOS3 gene promoter polymorphisms with circulating tumor cells PCA3 detection in the peripheral blood, as shown elsewhere with the 894G>T polymorphism and the PCA3 detection [24].
###end p 98
###begin p 99
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 193 195 193 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 218 223 218 223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 269 275 269 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FOLH1 </italic>
###xml 352 360 <span type="species:ncbi:9606">patients</span>
The PCA3 gene is a highly specific prostate tumor biomarker that is not found in other kinds of cells and tissues, whereas its detection on peripheral blood may indicate a possible metastasis [20]. We believe that the PCA3 is more specific for tumor detection than the FOLH1 marker, which presents a high variation on gene expression among PCa and BPH patients and its utilization as a biomarker is highly controversial (unpublished data).
###end p 99
###begin p 100
###xml 20 25 20 25 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
In the overall, the PCA3 clinical parameters for PCa cell detection in the peripheral blood were: 35.0% of sensitivity (25 out of 71), and 81.0% of specificity (63 out of 78); however, it is important to observe that a positive result is not an indication of metastasis and that some BPH cases may have been misdiagnosed, reducing its true clinical value.
###end p 100
###begin p 101
###xml 13 18 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 332 337 332 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 469 474 469 474 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 151 159 <span type="species:ncbi:9606">patients</span>
###xml 357 365 <span type="species:ncbi:9606">patients</span>
In fact, the PCA3 detection may become a potential biomarker for blood diagnosis, once it is exclusively detected in prostate cancer cells; therefore, patients histologically diagnosed as BPH may probably be tumor confined disease that was missed during biopsy sampling or by pathological examination. On the other hand, a negative PCA3 detection in cancer patients may also suggest that the tumor is organ confined. However, it is important to emphasize that positive PCA3 detection is not an indication of faster tumor development or invasiveness.
###end p 101
###begin p 102
###xml 631 636 631 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
Prostate cancer is a complex disease due to multifactorial and multifocal events caused by many biological mechanisms. These mechanisms are represented by differential gene expression profiles, generating disease developmental stages that vary from latent to aggressive forms. Therefore, detection of key genetic alterations at the molecular level may be a useful tool as a prognostic indicator. Despite the complexity of events that the NO participates in many biological processes, its association with carcinogenesis is critical once NO levels modulate tumor development. Part of this differential NO expression is regulated by NOS3 promoter polymorphisms, specifically the -786T>C, which may have an influence on the progression of the disease and not on its occurrence.
###end p 102
###begin p 103
###xml 264 269 264 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 369 374 369 374 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
There are at least five regulatory elements within the amplified promoter region (-820 to -583) and their interaction with all polymorphisms have not been investigated. Therefore, it is possible that other external and internal factors may independently influence NOS3 gene expression masking the true effect of polymorphisms, which may explain the high variability of NOS3 transcript levels observed within PCa and BPH groups.
###end p 103
###begin p 104
###xml 28 33 28 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 83 88 83 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 344 349 344 349 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 362 367 362 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 401 406 401 406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 419 424 419 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 88 96 <span type="species:ncbi:9606">patients</span>
###xml 282 290 <span type="species:ncbi:9606">patients</span>
In the present work, higher NOS3 transcript levels in peripheral blood of positive PCA3 patients than in negative ones suggest that tumor may be in a medium-late (pT2) stage of the disease and corroborates with the molecular approach for disease staging. Therefore, we propose that patients with differential expression/detection, such as high NOS3 and negative PCA3 may indicate pT1 stage, while low NOS3 and positive PCA3 may indicate pT3 or pT4 stages.
###end p 104
###begin title 105
Conclusion
###end title 105
###begin p 106
###xml 85 90 85 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 213 218 213 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 800 805 800 805 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 833 837 833 837 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 838 842 838 842 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M </italic>
###xml 925 930 925 930 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3 </italic>
###xml 982 987 982 987 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3 </italic>
###xml 313 321 <span type="species:ncbi:9606">patients</span>
In conclusion, this is the first publication that demonstrates an association of the NOS3 promoter region polymorphisms with prostate cancer progression. The strategy of determining genotypic conformations of the NOS3 promoter region through the SSCP technique demonstrated to be very effective in genotyping all patients, which were classified into four haplotypes and seven genotypic conformations. The C allele of the -786T>C polymorphism was always associated with at least two other mutations (haplotypes C, A and N), while the T haplotype (containing the T allele) had no mutations. Significant relative risks (> 3 fold) of cancer occurrence were related to the -786T>C polymorphism, and it is the most important promoter alteration that may affect the PCa progression, but not its occurrence. NOS3 transcript relative levels (NOS3:B2M > 0.8) were 4-fold higher in PCa than in BPH, and due to its bimodal behavior, the NOS3 levels may be used as a biomarker together with the PCA3 marker for molecular staging of the disease.
###end p 106
###begin title 107
Abbreviations
###end title 107
###begin p 108
###xml 18 22 18 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 251 254 251 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">vrs</italic>
###xml 256 262 256 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">versus</italic>
###xml 324 328 324 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PCA3</italic>
###xml 400 403 400 403 <italic xmlns:xlink="http://www.w3.org/1999/xlink">B2M</italic>
###xml 459 464 459 464 <italic xmlns:xlink="http://www.w3.org/1999/xlink">FOLH1</italic>
###xml 610 640 610 640 <italic xmlns:xlink="http://www.w3.org/1999/xlink">murine moloney leukemia virus </italic>
###xml 610 616 <span type="species:ncbi:10090">murine</span>
NO: nitric oxide; NOS3: nitric oxide synthase 3; PCa: prostate cancer; ROS: reactive oxygen species; bp: base pair; SSCP: single strand conformation polymorphism; BPH: benign prostatic hyperplasia; SNP: single nucleotide polymorphism; OR: odds ratio; vrs: versus; PSA: prostate specific antigen; TNM: tumor-node-metastasis; PCA3: prostate cancer antigen 3; TURP: transurethral resection of prostate; B2M: beta-2-microglobulin, PCR: polymerase chain reaction; FOLH1: folate hydrolase - prostate-specific membrane antigen; UFU: Federal University of Uberlandia; dNTP: desoxyribonucleotide triphosphate; MMLV-RT: murine moloney leukemia virus reverse transcriptase; DEPC: diethylpyrocarbonate; CNPq: National Counsel of Technological and Scientific Development; CAPES: Coordination of Perfectioning of Staff of Superior Level; FAPEMIG: Foundation of Support to the Research of the State of Minas Gerais.
###end p 108
###begin title 109
Competing interests
###end title 109
###begin p 110
The authors declare that they have no competing interests.
###end p 110
###begin title 111
Authors' contributions
###end title 111
###begin p 112
KM, TGA and AFN have equally contributed for the present study (research design, sample collection, processing, and analysis). LRG is senior author and wrote the paper with KM. The authors read and approved the final manuscript.
###end p 112
###begin title 113
Pre-publication history
###end title 113
###begin p 114
The pre-publication history for this paper can be accessed here:
###end p 114
###begin p 115

###end p 115
###begin title 116
Acknowledgements
###end title 116
###begin p 117
The authors would like to thank the medical staff from the Urology Division of the University Hospital for providing the biological samples and the clinical parameters and the financial support from CNPq, CAPES and FAPEMIG.
###end p 117
###begin article-title 118
Expressional control of the 'constitutive' isoforms of nitric oxide synthase (NOS I and NOS III)
###end article-title 118
###begin article-title 119
Compilation of vertebrate-encoded transcription factors
###end article-title 119
###begin article-title 120
###xml 59 63 59 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS3</italic>
###xml 85 90 <span type="species:ncbi:9606">human</span>
Estrogens increases the endothelial nitric oxide synthase (NOS3) mRNA level in LNPCa human prostate carcinoma cells
###end article-title 120
###begin article-title 121
DNA damage by nitric oxide (NO)
###end article-title 121
###begin article-title 122
###xml 89 111 89 111 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Salmonella typhimurium</italic>
###xml 51 56 <span type="species:ncbi:9606">human</span>
###xml 89 111 <span type="species:ncbi:90371">Salmonella typhimurium</span>
Nitric oxide-induced mutations in the HPRT gene of human lymphoblastoid TK6 cells and in Salmonella typhimurium
###end article-title 122
###begin article-title 123
Regulation of the hypoxia-inducible factor 1 alpha by inflammatory mediators' nitric oxide and tumor necrosis factor-alpha in contrast to desferroxamine and phenylarsine oxide
###end article-title 123
###begin article-title 124
RNA Interference - 2001
###end article-title 124
###begin article-title 125
Just say NO to cancer?
###end article-title 125
###begin article-title 126
Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer
###end article-title 126
###begin article-title 127
Is there a role for nitric oxide in tumor angiogenesis?
###end article-title 127
###begin article-title 128
###xml 47 52 <span type="species:ncbi:9606">human</span>
Cloning and structural characterization of the human endothelial nitric oxide synthase gene
###end article-title 128
###begin article-title 129
###xml 91 97 <span type="species:ncbi:9606">humans</span>
Evidence of association of the ecNOS gene polymorphism with plasma NO metabolite levels in humans
###end article-title 129
###begin article-title 130
###xml 48 53 <span type="species:ncbi:9606">human</span>
Gene structure, polymorphism and mapping of the human endothelial nitric oxide synthase gene
###end article-title 130
###begin article-title 131
Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
###end article-title 131
###begin article-title 132
###xml 1 5 1 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-786</sup>
T-786-->C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm
###end article-title 132
###begin article-title 133
###xml 29 34 <span type="species:ncbi:9606">human</span>
Detection of polymorphism of human DNA by gel eletrophoresis as single strand conformation polymorphism
###end article-title 133
###begin article-title 134
Improved silver staining of proteins, RNA and DNA in polyacrilamide gels
###end article-title 134
###begin article-title 135
Fast and sensitive silver staining of DNA in polyacrilamide gels
###end article-title 135
###begin article-title 136
DD3: A new prostate-specific gene, highly overexpressed in prostate cancer
###end article-title 136
###begin article-title 137
Outcome in prostate cancer: association with endothelial nitric oxide synthase Glu298Asp polymorphism at exon 7
###end article-title 137
###begin article-title 138
Endothelial nitric oxide synthase gene polymorphisms and genetics susceptibility to prostate cancer
###end article-title 138
###begin article-title 139
###xml 128 136 <span type="species:ncbi:9606">patients</span>
Endothelial nitric oxide synthase gene polymorphism and the shedding of circulating tumor cells in the blood of prostate cancer patients
###end article-title 139
###begin article-title 140
###xml 114 122 <span type="species:ncbi:9606">patients</span>
The endothelial nitric oxide synthase Glu-298-Asp polymorphism and its mRNA expression in the peripheral blood of patients with prostate cancer and benign prostatic hyperplasia
###end article-title 140
###begin article-title 141
###xml 1 5 1 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-786</sup>
T-786-->C mutation in the 5'-flanking region of the endothelial nitric oxide synthase gene is associated with myocardial infarction, especially without coronary organic stenosis
###end article-title 141
###begin article-title 142
Endothelial nitric oxide synthase gene sequence variations and vascular disease
###end article-title 142
###begin article-title 143
Genotype-dependent expression of endothelial nitric oxide synthase (eNOS) and its regulatory proteins in cultured endothelial cells
###end article-title 143
###begin article-title 144
Role of nitric oxide in genotoxicity: implication for carcinogenesis
###end article-title 144
###begin article-title 145
Role of nitric oxide in angiogenesis and microcirculation in tumors
###end article-title 145
###begin article-title 146
Molecular biology of nitric oxide synthases
###end article-title 146
###begin article-title 147
Role of nitric oxide in IL-2 therapy induced capillary leak syndrome
###end article-title 147
###begin article-title 148
Suppression of apoptosis by nitric oxide via inhibition of interleukin-1beta-converting enzyme (ICE)-like and cysteine protease protein (CCP)-32-like proteases
###end article-title 148

